Veradermics reports 23.3 hair count increase in trial

• Veradermics announced that patients in its Phase 2 clinical trial for VDPHL01 experienced an average increase of up to 23.3 hairs per square centimeter over six months.
• The company reported no treatment-related serious adverse events or cardiac issues, supporting the overall safety profile of the oral formulation.
• Management stated the results strengthen its conviction in the ongoing Phase 3 trial, with topline data anticipated in the first half of 2027.

Veradermics (NYSE:MANE) reported that its VDPHL01 treatment produced an average increase of up to 23.3 hairs per square centimeter in female patients over six months.

The Phase 2 clinical trial results demonstrated a consistent patient response compared to the historical reliance on topical over-the-counter options and unproven supplements.

The data showed 88.9% of participants on a once-daily 4.5mg dose and 90% on a twice-daily 4.5mg dose reported improved hair coverage.

Following the announcement, Veradermics share price was up at $112.37.

Veradermics stated it is actively recruiting female participants for its extensive pivotal Phase 3 trial to support a potential regulatory approval.

The business also completed enrollment for its second Phase 3 male trial, with management anticipating topline results for that cohort in the second half of 2026.